The Experts below are selected from a list of 1803 Experts worldwide ranked by ideXlab platform
Fatima Ochoagonzalez - One of the best experts on this subject based on the ideXlab platform.
-
metformin induces cell cycle arrest reduced proliferation Wound Healing Impairment in vivo and is associated to clinical outcomes in diabetic foot ulcer patients
PLOS ONE, 2016Co-Authors: Alberto R Cervantesvillagrana, Julio C Fernandezruiz, Fatima Ochoagonzalez, Hilda Susana Navaramirez, Adriana C Hernandezcorrea, Jose A Encisomoreno, Julio E CastanedadelgadoAbstract:There is an error in affiliation for author Julio E. Castaneda-Delgado. The correct affiliation should be: CONACYT—Unidad de Investigacion Biomedica de Zacatecas, Instituto Mexicano del Seguro Social (IMSS), Zacatecas, Zac., Mexico.
-
metformin induces cell cycle arrest reduced proliferation Wound Healing Impairment in vivo and is associated to clinical outcomes in diabetic foot ulcer patients
PLOS ONE, 2016Co-Authors: Alberto R Cervantesvillagrana, Julio C Fernandezruiz, Fatima Ochoagonzalez, Hilda Susana Navaramirez, Adriana C Hernandezcorrea, Jose A Encisomoreno, Julio E CastanedadelgadoAbstract:Background Several epidemiological studies in diabetic patients have demonstrated a protective effect of metformin to the development of several types of cancer. The underlying mechanisms of such phenomenon is related to the effect of metformin on cell proliferation among which, mTOR, AMPK and other targets have been identified. However, little is known about the role that metformin treatment have on other cell types such as keratinocytes and whether exposure to metformin of these cells might have serious repercussions in Wound Healing delay and in the development of complications in diabetic patients with foot ulcers or in their exacerbation. Material and Methods HaCaT Cells were exposed to various concentrations of metformin and cell viability was evaluated by a Resazurin assay; Proliferation was also evaluated with a colony formation assay and with CFSE dilution assay by flow cytometry. Cell cycle was also evaluated by flow cytometry by PI staining. An animal model of Wound Healing was used to evaluate the effect of metformin in Wound closure. Also, an analysis of patients receiving metformin treatment was performed to determine the effect of metformin treatment on the outcome and Wound area. Statistical analysis was performed on SPSS v. 18 and GraphPad software v.5. Results Metformin treatment significantly reduces cell proliferation; colony formation and alterations of the cell cycle are observed also in the metformin treated cells, particularly in the S phase. There is a significant increase in the area of the Wound of the metformin treated animals at different time points (P<0.05). There is also a significant increase in the size and Wound area of the patients with diabetic foot ulcers at the time of hospitalization. A protective effect of metformin was observed for amputation, probably associated with the anti inflammatory effects reported of metformin. Conclusions Metformin treatment reduces cell proliferation and reduces Wound Healing in an animal model and affects clinical outcomes in diabetic foot ulcer patients. Chronic use of this drug should be further investigated to provide evidence of their security in association with DFU.
Julio E Castanedadelgado - One of the best experts on this subject based on the ideXlab platform.
-
metformin induces cell cycle arrest reduced proliferation Wound Healing Impairment in vivo and is associated to clinical outcomes in diabetic foot ulcer patients
PLOS ONE, 2016Co-Authors: Alberto R Cervantesvillagrana, Julio C Fernandezruiz, Fatima Ochoagonzalez, Hilda Susana Navaramirez, Adriana C Hernandezcorrea, Jose A Encisomoreno, Julio E CastanedadelgadoAbstract:There is an error in affiliation for author Julio E. Castaneda-Delgado. The correct affiliation should be: CONACYT—Unidad de Investigacion Biomedica de Zacatecas, Instituto Mexicano del Seguro Social (IMSS), Zacatecas, Zac., Mexico.
-
metformin induces cell cycle arrest reduced proliferation Wound Healing Impairment in vivo and is associated to clinical outcomes in diabetic foot ulcer patients
PLOS ONE, 2016Co-Authors: Alberto R Cervantesvillagrana, Julio C Fernandezruiz, Fatima Ochoagonzalez, Hilda Susana Navaramirez, Adriana C Hernandezcorrea, Jose A Encisomoreno, Julio E CastanedadelgadoAbstract:Background Several epidemiological studies in diabetic patients have demonstrated a protective effect of metformin to the development of several types of cancer. The underlying mechanisms of such phenomenon is related to the effect of metformin on cell proliferation among which, mTOR, AMPK and other targets have been identified. However, little is known about the role that metformin treatment have on other cell types such as keratinocytes and whether exposure to metformin of these cells might have serious repercussions in Wound Healing delay and in the development of complications in diabetic patients with foot ulcers or in their exacerbation. Material and Methods HaCaT Cells were exposed to various concentrations of metformin and cell viability was evaluated by a Resazurin assay; Proliferation was also evaluated with a colony formation assay and with CFSE dilution assay by flow cytometry. Cell cycle was also evaluated by flow cytometry by PI staining. An animal model of Wound Healing was used to evaluate the effect of metformin in Wound closure. Also, an analysis of patients receiving metformin treatment was performed to determine the effect of metformin treatment on the outcome and Wound area. Statistical analysis was performed on SPSS v. 18 and GraphPad software v.5. Results Metformin treatment significantly reduces cell proliferation; colony formation and alterations of the cell cycle are observed also in the metformin treated cells, particularly in the S phase. There is a significant increase in the area of the Wound of the metformin treated animals at different time points (P<0.05). There is also a significant increase in the size and Wound area of the patients with diabetic foot ulcers at the time of hospitalization. A protective effect of metformin was observed for amputation, probably associated with the anti inflammatory effects reported of metformin. Conclusions Metformin treatment reduces cell proliferation and reduces Wound Healing in an animal model and affects clinical outcomes in diabetic foot ulcer patients. Chronic use of this drug should be further investigated to provide evidence of their security in association with DFU.
Christopher J. Murphy - One of the best experts on this subject based on the ideXlab platform.
-
full thickness splinted skin Wound Healing models in db db and heterozygous mice implications for Wound Healing Impairment
Wound Repair and Regeneration, 2014Co-Authors: Shin Ae Park, Leandro B. C. Teixeira, Vijay Krishna Raghunathan, Jill Covert, Richard R. Dubielzig, Roslyn Rivkah Isseroff, Michael J. Schurr, Nicholas L. Abbott, Jonathan F. Mcanulty, Christopher J. MurphyAbstract:The excisional dorsal full-thickness skin Wound model with or without splinting is widely utilized in Wound Healing studies using diabetic or normal mice. However, the effects of splinting on dermal Wound Healing have not been fully characterized, and there are limited data on the direct comparison of Wound parameters in the splinted model between diabetic and normal mice. We compared full-thickness excisional dermal Wound Healing in db/db and heterozygous mice by investigating the effects of splinting, semi-occlusive dressing, and poly(ethylene glycol) treatment. Two 8-mm full-thickness Wounds were made with or without splinting in db/db and heterozygous mice. Body weights, splint maintenance, Wound contraction, Wound closure, and histopathological parameters including reepithelialization, Wound bed collagen deposition, and inflammation were compared between groups. Our results show that silicone splint application effectively reduced Wound contraction in heterozygous and db/db mice. Splinted Wounds, as opposed to nonsplinted Wounds, exhibited no significant differences in Wound closure between heterozygous and db/db mice. Finally, polyethylene glycol and the noncontact dressing had no significant effect on Wound Healing in heterozygous or db/db mice. We believe these findings will help investigators in selection of the appropriate Wound model and data interpretation with fully defined parameters.
Dorthe Seidel - One of the best experts on this subject based on the ideXlab platform.
-
negative pressure Wound therapy vs conventional Wound treatment in subcutaneous abdominal Wound Healing Impairment the sawhi randomized clinical trial
JAMA Surgery, 2020Co-Authors: Dorthe Seidel, Stephan Diedrich, F Herrle, Henryk Thielemann, Frank Marusch, Rebekka Schirren, Recca Talaulicar, Tobias Gehrig, Nadja Lehwaldtywuschik, M GlanemannAbstract:Importance Negative pressure Wound therapy (NPWT) is an established treatment option, but there is no evidence of benefit for subcutaneous abdominal Wound Healing Impairment (SAWHI). Objective To evaluate the effectiveness and safety of NPWT for SAWHI after surgery in clinical practice. Design, Setting, and Participants The multicenter, multinational, observer-blinded, randomized clinical SAWHI study enrolled patients between August 2, 2011, and January 31, 2018. The last follow-up date was June 11, 2018. The trial included 34 abdominal surgical departments of hospitals in Germany, Belgium, and the Netherlands, and 539 consecutive, compliant adult patients with SAWHI after surgery without fascia dehiscence were randomly assigned to the treatment arms in a 1:1 ratio stratified by study site and Wound size using a centralized web-based tool. A total of 507 study participants (NPWT, 256; CWT, 251) were assessed for the primary end point in the modified intention-to-treat (ITT) population. Interventions Negative pressure Wound therapy and conventional Wound treatment (CWT). Main Outcomes and Measures The primary outcome was time until Wound closure (delayed primary closure or by secondary intention) within 42 days. Safety analysis comprised the adverse events (AEs). Secondary outcomes included Wound closure rate, quality of life (SF-36), pain, and patient satisfaction. Results Of the 507 study participants included in the modified ITT population, 287 were men (56.6%) (NPWT, 155 [60.5%] and CWT, 132 [52.6%]) and 220 were women (43.4%) (NPWT, 101 [39.5%] and CWT 119 [47.4%]). The median (IQR) age of the participants was 66 (18) years in the NPWT arm and 66 (20) years in the CWT arm. Mean time to Wound closure was significantly shorter in the NPWT arm (36.1 days) than in the CWT arm (39.1 days) (difference, 3.0 days; 95% CI 1.6-4.4;P Conclusions and Relevance Negative pressure Wound therapy is an effective treatment option for SAWHI after surgery; however, it causes more Wound-related AEs. Trial Registration ClinicalTrials.gov Identifier:NCT01528033
-
treatment of subcutaneous abdominal Wound Healing Impairment after surgery without fascial dehiscence by vacuum assisted closure sawhi v a c study versus standard conventional Wound therapy study protocol for a randomized controlled trial
Trials, 2013Co-Authors: Dorthe Seidel, Rolf Lefering, Edmund NeugebauerAbstract:Background A decision of the Federal Joint Committee Germany in 2008 stated that negative pressure Wound therapy is not accepted as a standard therapy for full reimbursement by the health insurance companies in Germany. This decision is based on the final report of the Institute for Quality and Efficiency in Health Care in 2006, which demonstrated through systematic reviews and meta-analysis of previous study projects, that an insufficient state of evidence regarding the use of negative pressure Wound therapy for the treatment of acute and chronic Wounds exists. Further studies were therefore indicated.
-
treatment of subcutaneous abdominal Wound Healing Impairment after surgery without fascial dehiscence by vacuum assisted closure sawhi v a c study versus standard conventional Wound therapy study protocol for a randomized controlled trial
Trials, 2013Co-Authors: Dorthe Seidel, Rolf Lefering, Edmund NeugebauerAbstract:A decision of the Federal Joint Committee Germany in 2008 stated that negative pressure Wound therapy is not accepted as a standard therapy for full reimbursement by the health insurance companies in Germany. This decision is based on the final report of the Institute for Quality and Efficiency in Health Care in 2006, which demonstrated through systematic reviews and meta-analysis of previous study projects, that an insufficient state of evidence regarding the use of negative pressure Wound therapy for the treatment of acute and chronic Wounds exists. Further studies were therefore indicated. The study is designed as a multinational, multicenter, prospective randomized controlled, adaptive design, clinical superiority trial, with blinded photographic analysis of the primary endpoint. Efficacy and effectiveness of negative pressure Wound therapy for Wounds in both medical sectors (in- and outpatient care) will be evaluated. The trial compares the treatment outcome of the application of a technical medical device which is based on the principle of negative pressure Wound therapy (intervention group) and standard conventional Wound therapy (control group) in the treatment of subcutaneous abdominal Wounds after surgery. The aim of the SAWHI-VAC® study is to compare the clinical, safety and economic results of both treatment arms. The study project is designed and conducted with the aim of providing solid evidence regarding the efficacy of negative pressure Wound therapy. Study results will be provided until the end of 2014 to contribute to the final decision of the Federal Joint Committee Germany regarding the general admission of negative pressure Wound therapy as a standard of performance within both medical sectors. Clinical Trials.gov NCT01528033 German Clinical Trials Register DRKS00000648
M Glanemann - One of the best experts on this subject based on the ideXlab platform.
-
negative pressure Wound therapy vs conventional Wound treatment in subcutaneous abdominal Wound Healing Impairment the sawhi randomized clinical trial
JAMA Surgery, 2020Co-Authors: Dorthe Seidel, Stephan Diedrich, F Herrle, Henryk Thielemann, Frank Marusch, Rebekka Schirren, Recca Talaulicar, Tobias Gehrig, Nadja Lehwaldtywuschik, M GlanemannAbstract:Importance Negative pressure Wound therapy (NPWT) is an established treatment option, but there is no evidence of benefit for subcutaneous abdominal Wound Healing Impairment (SAWHI). Objective To evaluate the effectiveness and safety of NPWT for SAWHI after surgery in clinical practice. Design, Setting, and Participants The multicenter, multinational, observer-blinded, randomized clinical SAWHI study enrolled patients between August 2, 2011, and January 31, 2018. The last follow-up date was June 11, 2018. The trial included 34 abdominal surgical departments of hospitals in Germany, Belgium, and the Netherlands, and 539 consecutive, compliant adult patients with SAWHI after surgery without fascia dehiscence were randomly assigned to the treatment arms in a 1:1 ratio stratified by study site and Wound size using a centralized web-based tool. A total of 507 study participants (NPWT, 256; CWT, 251) were assessed for the primary end point in the modified intention-to-treat (ITT) population. Interventions Negative pressure Wound therapy and conventional Wound treatment (CWT). Main Outcomes and Measures The primary outcome was time until Wound closure (delayed primary closure or by secondary intention) within 42 days. Safety analysis comprised the adverse events (AEs). Secondary outcomes included Wound closure rate, quality of life (SF-36), pain, and patient satisfaction. Results Of the 507 study participants included in the modified ITT population, 287 were men (56.6%) (NPWT, 155 [60.5%] and CWT, 132 [52.6%]) and 220 were women (43.4%) (NPWT, 101 [39.5%] and CWT 119 [47.4%]). The median (IQR) age of the participants was 66 (18) years in the NPWT arm and 66 (20) years in the CWT arm. Mean time to Wound closure was significantly shorter in the NPWT arm (36.1 days) than in the CWT arm (39.1 days) (difference, 3.0 days; 95% CI 1.6-4.4;P Conclusions and Relevance Negative pressure Wound therapy is an effective treatment option for SAWHI after surgery; however, it causes more Wound-related AEs. Trial Registration ClinicalTrials.gov Identifier:NCT01528033
